Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity
Doxorubicin (Dox) is one of the most frequently used chemotherapeutic drugs in a variety of cancers, but Dox-induced cardiotoxicity diminishes its therapeutic efficacy. The underlying mechanisms of Dox-induced cardiotoxicity are still not fully understood. More significantly, there are no establishe...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/11/4294 |
| _version_ | 1797597107617529856 |
|---|---|
| author | Natticha Sumneang Pongpan Tanajak Thura Tun Oo |
| author_facet | Natticha Sumneang Pongpan Tanajak Thura Tun Oo |
| author_sort | Natticha Sumneang |
| collection | DOAJ |
| description | Doxorubicin (Dox) is one of the most frequently used chemotherapeutic drugs in a variety of cancers, but Dox-induced cardiotoxicity diminishes its therapeutic efficacy. The underlying mechanisms of Dox-induced cardiotoxicity are still not fully understood. More significantly, there are no established therapeutic guidelines for Dox-induced cardiotoxicity. To date, Dox-induced cardiac inflammation is widely considered as one of the underlying mechanisms involved in Dox-induced cardiotoxicity. The Toll-like receptor 4 (TLR4) signaling pathway plays a key role in Dox-induced cardiac inflammation, and growing evidence reports that TLR4-induced cardiac inflammation is strongly linked to Dox-induced cardiotoxicity. In this review, we outline and address all the available evidence demonstrating the involvement of the TLR4 signaling pathway in different models of Dox-induced cardiotoxicity. This review also discusses the effect of the TLR4 signaling pathway on Dox-induced cardiotoxicity. Understanding the role of the TLR4 signaling pathway in Dox-induced cardiac inflammation might be beneficial for developing a potential therapeutic strategy for Dox-induced cardiotoxicity. |
| first_indexed | 2024-03-11T03:02:07Z |
| format | Article |
| id | doaj.art-e54bc7605db149d5b5e6bfe4e4348f1b |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-11T03:02:07Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-e54bc7605db149d5b5e6bfe4e4348f1b2023-11-18T08:14:40ZengMDPI AGMolecules1420-30492023-05-012811429410.3390/molecules28114294Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced CardiotoxicityNatticha Sumneang0Pongpan Tanajak1Thura Tun Oo2Department of Medical Science, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, ThailandDepartment of Physical Therapy, Rehabilitation Center, Apinop Wetchakam Hospital, Kaeng-Khoi District, Saraburi 18110, ThailandDepartment of Biomedical Sciences, University of Illinois at Chicago, College of Medicine Rockford, Rockford, IL 61107, USADoxorubicin (Dox) is one of the most frequently used chemotherapeutic drugs in a variety of cancers, but Dox-induced cardiotoxicity diminishes its therapeutic efficacy. The underlying mechanisms of Dox-induced cardiotoxicity are still not fully understood. More significantly, there are no established therapeutic guidelines for Dox-induced cardiotoxicity. To date, Dox-induced cardiac inflammation is widely considered as one of the underlying mechanisms involved in Dox-induced cardiotoxicity. The Toll-like receptor 4 (TLR4) signaling pathway plays a key role in Dox-induced cardiac inflammation, and growing evidence reports that TLR4-induced cardiac inflammation is strongly linked to Dox-induced cardiotoxicity. In this review, we outline and address all the available evidence demonstrating the involvement of the TLR4 signaling pathway in different models of Dox-induced cardiotoxicity. This review also discusses the effect of the TLR4 signaling pathway on Dox-induced cardiotoxicity. Understanding the role of the TLR4 signaling pathway in Dox-induced cardiac inflammation might be beneficial for developing a potential therapeutic strategy for Dox-induced cardiotoxicity.https://www.mdpi.com/1420-3049/28/11/4294doxorubicinToll-like receptor 4cardiotoxicityheart |
| spellingShingle | Natticha Sumneang Pongpan Tanajak Thura Tun Oo Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity Molecules doxorubicin Toll-like receptor 4 cardiotoxicity heart |
| title | Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity |
| title_full | Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity |
| title_fullStr | Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity |
| title_full_unstemmed | Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity |
| title_short | Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity |
| title_sort | toll like receptor 4 inflammatory perspective on doxorubicin induced cardiotoxicity |
| topic | doxorubicin Toll-like receptor 4 cardiotoxicity heart |
| url | https://www.mdpi.com/1420-3049/28/11/4294 |
| work_keys_str_mv | AT nattichasumneang tolllikereceptor4inflammatoryperspectiveondoxorubicininducedcardiotoxicity AT pongpantanajak tolllikereceptor4inflammatoryperspectiveondoxorubicininducedcardiotoxicity AT thuratunoo tolllikereceptor4inflammatoryperspectiveondoxorubicininducedcardiotoxicity |